ClinicalTrials.gg
RecruitingNCT07610005Updated Oct 29, 2026

A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants

A Phase 1 interventional study of Varegacestat Reference Formulation and Varegacestat Test Formulation A in Healthy, sponsored by Immunome, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Immunome, Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Oct 29, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is an open-label, randomized, crossover study to evaluate the relative bioavailability (rBA) and bioequivalence (BE) of a test capsule formulation of varegacestat compared to reference capsules formulation under fasting conditions.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Immunome, Inc. is the lead sponsor of 11 studies on the registry; 5 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, adult, female of non or male, 18 to 55 years of age, inclusive, at the screening visit
  • Male participants must follow protocol-specified guidance
  • Continuous non-smoker who has not used nicotine and tobacco containing products for at least 3 months prior to the first dosing
  • ≥ 18.0 and ≤ 32.0 kg/m2 and with a body weight > 50 kg at the screening visit
  • Medically healthy with no medical history, physical examination, clinical laboratory profiles, vital signs, and ECGs, as deemed by the PI or designee
  • Able to swallow multiple capsules

Exclusion criteria

Exclusion Criteria:

  • Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study
  • History or presence of medical or psychiatric condition or disease in the opinion of the PI or designee
  • History of any illness that, in the opinion of the PI or designee might confound the results of the study or poses an additional risk to the participant by their participation in the study
  • History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing
  • History or presence of or idiosyncratic reaction to varegacestat or related compounds
  • History or presence of:

    • disease such as rheumatoid arthritis or systemic lupus erythematosus
    • Thrombophlebitis or deep vein thrombosis
    • Hematologic or coagulation disorders
    • Liver disease or dysfunction; Gilbert's syndrome
    • Renal dysfunction or glomerulonephritis
    • Cancer (except treated basal cell carcinoma of the skin and cancer-free for 5 years, non basal or squamous cell carcinoma of the skin, and cervical carcinoma in situ)
    • Clinically significant cardiovascular, gastrointestinal, pulmonary, endocrine, central nervous system disorders, or other major active and uncontrolled disease in the opinion of the PI or designee.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Part 1: Reference Formulation, then Test Formulation A

    Drug: Varegacestat Reference Formulation · Drug: Varegacestat Test Formulation A

  • Experimental
    Part 1: Test Formulation A, then Reference Formulation

    Drug: Varegacestat Reference Formulation · Drug: Varegacestat Test Formulation A

  • Experimental
    Part 2: Reference Formulation, then Test Formulation B

    Drug: Varegacestat Reference Formulation · Drug: Varegacestat Test Formulation B

  • Experimental
    Part 2: Test Formulation B, then Reference Formulation

    Drug: Varegacestat Reference Formulation · Drug: Varegacestat Test Formulation B

  • Experimental
    Part 2: Reference Formulation, then Test Formulation C

    Drug: Varegacestat Reference Formulation · Drug: Varegacestat Test Formulation C

  • Experimental
    Part 2: Test Formulation C, then Reference Formulation

    Drug: Varegacestat Reference Formulation · Drug: Varegacestat Test Formulation C

Interventions

  • DrugVaregacestat Reference Formulation

    Oral administration

  • DrugVaregacestat Test Formulation A

    Oral administration

  • DrugVaregacestat Test Formulation B

    Oral administration

  • DrugVaregacestat Test Formulation C

    Oral administration

06

What researchers measure

Primary outcomes

  1. Evaluate the rBA of varegacestat by AUC0-t

    Time frame: Approximately 3 weeks

  2. Evaluate the rBA of varegacestat by AUC0-inf

    Time frame: Approximately 3 weeks

  3. Evaluate the rBA of varegacestat by Cmax

    Time frame: Approximately 3 weeks

Secondary outcomes

  1. Assess the safety and tolerability of varegacestat by incidence of treatment emergent adverse events

    Time frame: Approximately 4 weeks

  2. Assess the safety and tolerability of varegacestat by incidence of laboratory abnormalities

    Time frame: Approximately 3 weeks

  3. Assess the safety and tolerability of varegacestat by incidence of changes in vital signs from baseline

    Time frame: Approximately 3 weeks

  4. Assess the safety and tolerability of varegacestat by incidence of changes from baseline of 12-lead ECG assessments

    Time frame: Approximately 3 weeks

07

Study locations

1 of 1 sites recruiting
  • Celerion, Inc.
    Tempe, Arizona 85283, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2026 (actual). Primary completion is estimated for May 2027, 12 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Jun 2026 → May 2027 and completion Jun 2026 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
May 27, 2026
StartActual
May 21, 2026
Primary completionEst.
May 2027was Jun 2026
CompletionEst.
May 2027was Jun 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→May 2027
Oct 29, 2026
Study completion
Jun 2026→May 2027
Oct 29, 2026
Enrollment
20→44
Oct 29, 2026
Interventions
Added Drug: Varegacestat Test Formulation A·Drug: Varegacestat Test Formulation B·Drug: Varegacestat Test Formulation C; removed Drug: Varegacestat Test Formulation. Arm changed Reference Formulation, then Test Formulation→Part 1: Reference Formulation, then Test Formulation A; Test Formulation, then Reference Formulation→Part 1: Test Formulation A, then Reference Formulation. Arms added: Part 2: Reference Formulation, then Test Formulation B·Part 2: Test Formulation B, then Reference Formulation·Part 2: Reference Formulation, then Test Formulation C·Part 2: Test Formulation C, then Reference Formulation
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Primary completion Jun 2026→May 2027
    Study completion Jun 2026→May 2027
    Enrollment 20→44
    Interventions Added Drug: Varegacestat Test Formulation A·Drug: Varegacestat Test Formulation B·Drug: Varegacestat Test Formulation C; removed Drug: Varegacestat Test Formulation. Arm changed Reference Formulation, then Test Formulation→Part 1: Reference Formulation, then Test Formulation A; Test Formulation, then Reference Formulation→Part 1: Test Formulation A, then Reference Formulation. Arms added: Part 2: Reference Formulation, then Test Formulation B·Part 2: Test Formulation B, then Reference Formulation·Part 2: Reference Formulation, then Test Formulation C·Part 2: Test Formulation C, then Reference Formulation
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07610005
Lead sponsor
Immunome, Inc.
Responsible party
Sponsor
First posted
May 27, 2026
Start date
May 21, 2026
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Immunome Medical Monitor
Contact
info@immunome.com
425.939.7410

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion